New SCHWIND LASIK platform going strong at 6 months

Article

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

The multi-centric LASIK myopia study, conducted by Maria-Clara Arbelaez and colleagues, enrolled 358 eyes. Of all the eyes, 65% achieved a postoperative uncorrected visual acuity (UCVA) of 20/16 or better and 98% achieved a UCVA of 20/20 or better. Target refraction was also found to be good, with 96% of treated eyes falling into the ±0.5 D range.

Aberration-free treatments were also found to be very safe. More than 55% of eyes gained one or more lines of visual acuity after six months and the induction of higher order aberrations, compared with non-aspheric treatment, was minimal. The total RMS of postoperative higher order aberrations (for 6 mm analysis diameter) rose by an average of just 0.07 µm. This also resulted in higher contrast sensitivity for patients.

Importantly, good results were seen very shortly after treatment, with study participants attaining the same visual acuity as the preoperative best corrected vision just one day after the procedure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.